Seneb has built a robust preclinical and clinical pipeline using glycolipid replacement therapies are its primary focus. The progression of diseases such as Batten’s, Huntington’s and Parkinson’s Disease can be slowed or halted upon treatment with glycolipid therapies. Seneb is positioned to bring two products to NDA submission within five year. Our lead compounds, SNB-2401 and SNB-4050, alter disease progression and hold great promise as human therapeutics.

HomeOur TechnologyPipelineContract ResearchManagement Team


Seneb BioSciences, Inc.  •  3805 Old Easton Road  •  Doylestown, PA 18902  •  (267) 893-6571  •  info@senebbio.com